In the first quarter of 2026, Farmak, Ukraine’s leading pharmaceutical manufacturer, continued to expand its export geography and delivered 17 new medicinal products to 8 countries worldwide. Export development and the launch of products in new markets remain among the company’s key strategic priorities.
In particular, Farmak supplied the following products to the United Kingdom for the first time:
• a contrast agent for radiographic and CT examinations;
• a contrast agent for magnetic resonance imaging (MRI);
• an anti-inflammatory medicinal product for the treatment of sore throat in solution and spray forms.
Germany received a hormonal medicinal product used for the treatment of diabetes insipidus and for controlling bleeding from esophageal varices.
The following products were exported to Sudan:
• an injectable solution for the prevention and treatment of thrombosis;
• ophthalmic medicinal products.
For the first time, the company supplied three ophthalmic medicinal products to Vietnam.
In the first quarter of 2026, the company also supplied:
• to Thailand – hormonal injectable medicinal product used in the treatment of endocrine and neuroendocrine disorders, including acromegaly;
• to the UAE – a medicinal product for anesthesia;
• to Iraq – a cardiology medicinal product for the treatment of stable angina;
• to Oman – a medicinal product for the treatment of vitamin B and C deficiencies.
Today, the Farmak Group export geography covers 60 countries worldwide. The Group operates three manufacturing sites in Ukraine and Spain. The company’s production facilities and laboratory complex are certified in accordance with EU GMP (Good Manufacturing Practice) standards.
